Show simple item record

dc.contributor.authorNiespialowska-Steuden, M.M.
dc.contributor.authorGorog, Diana
dc.contributor.authorMarkides, V.
dc.date.accessioned2012-10-04T12:59:51Z
dc.date.available2012-10-04T12:59:51Z
dc.date.issued2012-06-01
dc.identifier.citationNiespialowska-Steuden , M M , Gorog , D & Markides , V 2012 , ' Novel antithrombotic agents for atrial fibrillation ' , Pharmacology & Therapeutics , vol. 134 , no. 3 , pp. 345-354 . https://doi.org/10.1016/j.pharmthera.2012.02.006
dc.identifier.issn0163-7258
dc.identifier.otherPURE: 950187
dc.identifier.otherPURE UUID: 5555a3f3-8d09-4905-8f82-2915633df580
dc.identifier.otherScopus: 84859789405
dc.identifier.urihttp://hdl.handle.net/2299/9052
dc.descriptionCopyright 2012 Elsevier B.V., All rights reserved.
dc.description.abstractAtrial fibrillation (AF) is the most common cardiac arrhythmia. It is estimated that 1 in 4 individuals aged 40 years or above will develop at least 1 episode of AF during their lifetime. Stroke is a leading cause of serious, long-term disability and death, and a major socioeconomic burden in developed countries. The major risk factor for thromboembolic stroke is AF. Oral antithrombotic treatment for AF patients has been limited to vitamin K antagonists for more than 60 years. Treatment with warfarin can reduce, but fails to abolish thromboembolic stroke associated with AF. Despite anticoagulation, patients with AF are at increased stroke risk. Furthermore, warfarin has important limitations namely, the limited time in therapeutic range, the need for INR monitoring, risk of major bleeding including stroke, and drug interactions. Recently there have been very exciting and important new advances in thromboprophylaxis for AF. Novel oral agents have been developed and evaluated clinically. These include direct thrombin inhibitors (dabigatran etexilate), oral selective factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and PAR-1 inhibitors (vorapaxar and atopaxar). Some of the new drugs have demonstrated promising results in the clinical studies, they are convenient in use and do not require monitoring. The downsides are lack of antidotes or specific blood assays to monitor the anticoagulant effect. This review evaluates traditional and novel approaches to thromboprophylaxis in patients with AF.en
dc.format.extent10
dc.language.isoeng
dc.relation.ispartofPharmacology & Therapeutics
dc.titleNovel antithrombotic agents for atrial fibrillationen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionPharmacology and Clinical Science Research
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dcterms.dateAccepted2012-06-01
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.pharmthera.2012.02.006
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record